A Review of Anticoagulants *ACPE-Accredited*

The podcast episode centers on anticoagulation, providing a detailed overview of various anticoagulant drugs and their mechanisms. It begins by differentiating between anticoagulants and antiplatelet agents, focusing on drugs affecting thrombin and factor Xa. The speakers discuss specific drugs like bivalirudin, argatroban, dabigatran, apixaban, rivaroxaban, and edoxaban, including their uses in treating VTE and preventing stroke in AFib patients. Warfarin is examined, with emphasis on its mechanism involving vitamin K recycling and the importance of dietary consistency. The discussion also covers practical considerations such as dose adjustments, monitoring parameters like INR, potential drug interactions, and reversal strategies for each anticoagulant.

Outlines

Part 1: Fundamentals, Terminology, and Risk Factors

Part 2: Direct Thrombin and Factor Xa Inhibitors (DOACs)

Part 3: Warfarin Management and Clinical Considerations

Part 4: Heparin, HIT, and Conclusion

Sign in to continue reading, translating and more.

Continue

A Review of Anticoagulants ACPE-Accredited

CorConsult Rx: Evidence-Based Medicine and Pharmacy

Part 1: Fundamentals, Terminology, and Risk Factors

Introduction to Anticoagulation: Terminology, Thrombin, and Factor Xa

VTE, Atrial Fibrillation, and Virchow's Triad: Risk Factors for Thromboembolism

Part 2: Direct Thrombin and Factor Xa Inhibitors (DOACs)

Direct Thrombin Inhibitors: Bivalirudin, Argatroban, and PCI Considerations

Dabigatran: An Oral Direct Thrombin Inhibitor, Dosage, and Side Effects

Factor Xa Inhibitors: Apixaban, Edoxaban, Rivaroxaban, and Betrixaban

DOACs: Efficacy, Safety, and Dosing Considerations

Part 3: Warfarin Management and Clinical Considerations

Warfarin: Mechanism of Action and Vitamin K Dependence

Warfarin: Advantages, Disadvantages, and Bridging Therapy

Warfarin: Monitoring, Dosing, and Reversal Strategies

Warfarin: Drug Interactions, Herbal Supplements, and Factor XI Inhibitors

Part 4: Heparin, HIT, and Conclusion

Unfractionated Heparin, HIT, and Episode Conclusion

CorConsult Rx: Evidence-Based Medicine and Pharmacy

Part 1: Fundamentals, Terminology, and Risk Factors

00:12Introduction to Anticoagulation: Terminology, Thrombin, and Factor Xa

Introduction to Anticoagulation: Terminology, Thrombin, and Factor Xa

03:51VTE, Atrial Fibrillation, and Virchow's Triad: Risk Factors for Thromboembolism

VTE, Atrial Fibrillation, and Virchow's Triad: Risk Factors for Thromboembolism

Part 2: Direct Thrombin and Factor Xa Inhibitors (DOACs)

07:18Direct Thrombin Inhibitors: Bivalirudin, Argatroban, and PCI Considerations

Direct Thrombin Inhibitors: Bivalirudin, Argatroban, and PCI Considerations

12:24Dabigatran: An Oral Direct Thrombin Inhibitor, Dosage, and Side Effects

Dabigatran: An Oral Direct Thrombin Inhibitor, Dosage, and Side Effects

20:52Factor Xa Inhibitors: Apixaban, Edoxaban, Rivaroxaban, and Betrixaban

Factor Xa Inhibitors: Apixaban, Edoxaban, Rivaroxaban, and Betrixaban

27:03DOACs: Efficacy, Safety, and Dosing Considerations

DOACs: Efficacy, Safety, and Dosing Considerations

Part 3: Warfarin Management and Clinical Considerations

31:23Warfarin: Mechanism of Action and Vitamin K Dependence

Warfarin: Mechanism of Action and Vitamin K Dependence

35:30Warfarin: Advantages, Disadvantages, and Bridging Therapy

Warfarin: Advantages, Disadvantages, and Bridging Therapy

42:47Warfarin: Monitoring, Dosing, and Reversal Strategies

Warfarin: Monitoring, Dosing, and Reversal Strategies

51:12Warfarin: Drug Interactions, Herbal Supplements, and Factor XI Inhibitors

Warfarin: Drug Interactions, Herbal Supplements, and Factor XI Inhibitors

Part 4: Heparin, HIT, and Conclusion

55:38Unfractionated Heparin, HIT, and Episode Conclusion

Unfractionated Heparin, HIT, and Episode Conclusion

A Review of Anticoagulants ACPE-Accredited